JP7846086B2 - Ikaros又はaiolosによって媒介される障害に対する有利な治療法 - Google Patents
Ikaros又はaiolosによって媒介される障害に対する有利な治療法Info
- Publication number
- JP7846086B2 JP7846086B2 JP2023507879A JP2023507879A JP7846086B2 JP 7846086 B2 JP7846086 B2 JP 7846086B2 JP 2023507879 A JP2023507879 A JP 2023507879A JP 2023507879 A JP2023507879 A JP 2023507879A JP 7846086 B2 JP7846086 B2 JP 7846086B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- administered
- composition according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026060896A JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063011P | 2020-08-07 | 2020-08-07 | |
| US63/063,011 | 2020-08-07 | ||
| US202163173160P | 2021-04-09 | 2021-04-09 | |
| US63/173,160 | 2021-04-09 | ||
| US202163212463P | 2021-06-18 | 2021-06-18 | |
| US63/212,463 | 2021-06-18 | ||
| PCT/US2021/045000 WO2022032132A1 (en) | 2020-08-07 | 2021-08-06 | Advantageous therapies for disorders mediated by ikaros or aiolos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026060896A Division JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538520A JP2023538520A (ja) | 2023-09-08 |
| JP2023538520A5 JP2023538520A5 (cg-RX-API-DMAC7.html) | 2024-08-15 |
| JP7846086B2 true JP7846086B2 (ja) | 2026-04-14 |
Family
ID=80118544
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507879A Active JP7846086B2 (ja) | 2020-08-07 | 2021-08-06 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
| JP2026060896A Pending JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026060896A Pending JP2026117027A (ja) | 2020-08-07 | 2026-04-02 | Ikaros又はaiolosによって媒介される障害に対する有利な治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230190760A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192450A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7846086B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230049678A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194438B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021322285B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002225A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173658A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300373A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001545A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI887465B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| SMT202600194T1 (it) * | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| CA3194351A1 (en) * | 2020-10-14 | 2022-04-21 | Christopher G. Nasveschuk | Tricyclic compounds to degrade neosubstrates for medical therapy |
| JP7863100B2 (ja) * | 2020-10-14 | 2026-05-20 | シーフォー セラピューティクス, インコーポレイテッド | Ikzf2又はikzf4を分解する三環式リガンド |
| JP7807110B2 (ja) * | 2021-08-27 | 2026-01-27 | ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド | イソインドリノン化合物およびその使用 |
| JP2025505687A (ja) * | 2022-02-09 | 2025-02-28 | シーフォー セラピューティクス, インコーポレイテッド | Cft7455のモルフィック形態及びその製造方法 |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024193641A1 (zh) * | 2023-03-21 | 2024-09-26 | 上海超阳药业有限公司 | 异吲哚啉衍生物和苯并吲哚衍生物及其应用 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Krasの分解のためのヘテロ二官能性化合物 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| CN121620373A (zh) * | 2024-07-26 | 2026-03-06 | 上海超阳药业有限公司 | 苯并吲哚衍生物的药物组合物、制备方法及用途 |
| WO2026065268A1 (en) * | 2024-09-29 | 2026-04-02 | Biofront Ltd | Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| CN120138159A (zh) * | 2025-04-30 | 2025-06-13 | 徐州医科大学 | Nup35基因作为胶质母细胞瘤诊断、预后及治疗靶点的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019241274A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012175481A1 (en) * | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| EP4717317A3 (en) * | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
-
2021
- 2021-08-06 AU AU2021322285A patent/AU2021322285B2/en active Active
- 2021-08-06 WO PCT/US2021/045000 patent/WO2022032132A1/en not_active Ceased
- 2021-08-06 BR BR112023002225A patent/BR112023002225A2/pt unknown
- 2021-08-06 CA CA3173658A patent/CA3173658A1/en active Pending
- 2021-08-06 KR KR1020237007995A patent/KR20230049678A/ko active Pending
- 2021-08-06 MX MX2023001545A patent/MX2023001545A/es unknown
- 2021-08-06 CN CN202180066994.5A patent/CN116194438B/zh active Active
- 2021-08-06 IL IL300373A patent/IL300373A/en unknown
- 2021-08-06 JP JP2023507879A patent/JP7846086B2/ja active Active
- 2021-08-06 TW TW110129154A patent/TWI887465B/zh active
- 2021-08-06 EP EP21853504.5A patent/EP4192450A4/en active Pending
-
2023
- 2023-02-07 US US18/106,893 patent/US20230190760A1/en active Pending
-
2026
- 2026-04-02 JP JP2026060896A patent/JP2026117027A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019241274A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3173658A1 (en) | 2022-02-10 |
| EP4192450A1 (en) | 2023-06-14 |
| AU2021322285A1 (en) | 2023-04-13 |
| JP2023538520A (ja) | 2023-09-08 |
| BR112023002225A2 (pt) | 2023-03-07 |
| KR20230049678A (ko) | 2023-04-13 |
| US20230190760A1 (en) | 2023-06-22 |
| TWI887465B (zh) | 2025-06-21 |
| IL300373A (en) | 2023-04-01 |
| MX2023001545A (es) | 2023-05-03 |
| JP2026117027A (ja) | 2026-07-14 |
| CN116194438A (zh) | 2023-05-30 |
| AU2021322285B2 (en) | 2026-08-13 |
| WO2022032132A1 (en) | 2022-02-10 |
| CN116194438B (zh) | 2026-08-07 |
| TW202220981A (zh) | 2022-06-01 |
| EP4192450A4 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230190760A1 (en) | Advantageous therapies for disorders mediated by ikaros or aiolos | |
| US20240018118A1 (en) | Tricyclic compounds to degrade neosubstrates for medical therapy | |
| JP7863100B2 (ja) | Ikzf2又はikzf4を分解する三環式リガンド | |
| JP2024523839A (ja) | 突然変異体brafを分解する療法薬 | |
| BR112021000049A2 (pt) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona e seu uso no tratamento de doenças dependentes de dedo de zinco da família ikaros 2 (ikzf2) | |
| BR112021015672A2 (pt) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos | |
| WO2018005863A1 (en) | Pyrimidine-based compounds for the treatment of cancer | |
| JP2023536164A (ja) | ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 | |
| US20240391912A1 (en) | Morphic forms of cft7455 and methods of manufacture thereof | |
| JP2024521791A (ja) | 脳又はcnsへの癌転移を治療するためのegfrデグレーダー | |
| JP2025540907A (ja) | Ret-lddタンパク質分解誘導剤 | |
| RU2844734C1 (ru) | Преимущественные терапии нарушений, опосредованных ikaros или aiolos | |
| US20250289827A1 (en) | Morphic forms of a mutant braf degrader and methods of manufacture thereof | |
| CN118660884A (zh) | Cft7455的晶型物及其制造方法 | |
| JP2025540906A (ja) | Ret-lddタンパク質阻害剤 | |
| WO2025129116A1 (en) | Compounds for the targeted degradation of smarca2 | |
| BR112019027967A2 (pt) | forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240806 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250722 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251020 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260402 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7846086 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |